Day One Biopharmaceuticals reported preliminary 2025 net product revenue of $155.4 million for Ojemda, up 172% year over year, with approximately $52.8 million booked in the fourth quarter and 1,394 prescriptions in the period. The company guided to $225–$250 million in 2026 U.S. net product revenue for Ojemda and outlined a 2026–2028 plan anchored by expanding second-line pediatric low-grade glioma use, ex-U.S. commercialization via a partner, and completion of enrollment in the pivotal, first-line Firefly-2 trial in the first half of 2026, setting up a mid-2027 readout and a potential 2028 approval. Following the acquisition of Mersana, Day One added emiltatug ledadotin (emi-le), a B7-H4–targeted antibody-drug conjugate in adenoid cystic carcinoma, and expects phase 1 data by mid-2026, alongside initial phase 1a data for PTK7-targeted ADC DAY301 in the second half. The company ended 2025 with about $441.1 million in cash and investments prior to the Mersana deal.
The guidance signals a company attempting to cross a familiar biotech chasm: converting a single-asset pediatric franchise into a durable, multi-asset oncology platform. The near-term bet is that Ojemda can sustain double-digit quarterly growth through persistency and new starts in a niche population, while the medium-term hedge is pipeline diversification into ADCs. The strategic question is whether commercial momentum in a rare pediatric setting can reliably fund and de-risk expansion into broader oncology, particularly as payers tighten evidence expectations and competitors vie for earlier-line positioning.
This matters now because Ojemda’s trajectory will influence how clinicians sequence targeted therapies in pLGG and how payers define value in small-population oncology. Second-line adoption is rising as molecular testing uncovers more BRAF-driven disease, but front-line success would reshape care pathways and challenge entrenched regimens, including BRAF/MEK combinations already approved in pediatric settings. For patients and families, steady uptake suggests better access to a targeted option beyond chemotherapy, but real-world durability, toxicity management, and quality-of-life gains will be scrutinized. For payers, a move toward standard-of-care status in second line and potential first-line use will trigger demands for comparative effectiveness, adherence data, and resource utilization metrics to justify premium pricing. For HCPs and centers of excellence, the imperative is systematic genomic profiling to correctly identify BRAF fusions and non-V600 alterations and to build standardized referral and monitoring pathways that support persistency.
The Mersana acquisition aligns Day One with a broader industry pivot back into ADCs after a period of correction, with companies concentrating on validated targets and clearer development paths. A B7-H4 program positions Day One in an emerging immuno-oncology niche with potential tumor-agnostic relevance, while PTK7 adds optionality in solid tumors. For business development teams, this is a case study in revenue-backed pipeline building: use a focused commercial beachhead to finance later-stage assets rather than relying on dilutive capital in a volatile market. For competitors, the bar in pLGG will be set not only by response rates but by clean safety, long-term neurocognitive outcomes, and payer-accepted endpoints; in ADCs, differentiation on target selection, linker-payload design, and patient selection will be decisive.
The next 18 months will determine whether Day One’s rare-disease commercial engine can underwrite a credible adult oncology expansion. Watch for persistency trends, ex-U.S. HTA outcomes, and the Firefly-2 enrollment cadence as leading indicators, and ask whether forthcoming frontline data can displace existing standards without onerous step edits—or whether the company will need to lean on real-world evidence to unlock the next leg of growth.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
